Key features and details
- Mouse monoclonal [F8/86] to Von Willebrand Factor
- Suitable for: IHC-P, IHC-Fr
- Reacts with: Human
- Isotype: IgG1
Product nameAnti-Von Willebrand Factor antibody [F8/86]
See all Von Willebrand Factor primary antibodies
DescriptionMouse monoclonal [F8/86] to Von Willebrand Factor
Tested applicationsSuitable for: IHC-P, IHC-Frmore details
Species reactivityReacts with: Human
Predicted to work with: Rabbit
Von Willebrand Factor isolated from human plasma.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: Tissue culture supernatant, 1% BSA
Concentration information loading...
PurityTissue culture supernatant
Light chain typekappa
Our Abpromise guarantee covers the use of ab778 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/15 - 1/30. Perform enzymatic antigen retrieval before commencing with IHC staining protocol.|
|IHC-Fr||1/15 - 1/30. ABC method. We suggest an incubation period of 60 minutes at room temperature.|
FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains.
DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
modificationsAll cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
- Information by UniProt
- Coagulation factor VIII antibody
- Coagulation factor VIII VWF antibody
- F8VWF antibody
ab778 has been referenced in 9 publications.
- Zhang W et al. Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway. Exp Cell Res 370:333-342 (2018). PubMed: 29964051
- Chen JH et al. Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage. Mol Med Rep 17:1651-1659 (2018). PubMed: 29257200
- Wang Y et al. The transplantation of Akt-overexpressing amniotic fluid-derived mesenchymal stem cells protects the heart against ischemia-reperfusion injury in rabbits. Mol Med Rep 14:234-42 (2016). IHC-P ; Rabbit . PubMed: 27151366
- Lee DY et al. Synergistic effect of laminin and mesenchymal stem cells on tracheal mucosal regeneration. Biomaterials 44:134-42 (2015). IHC-P ; Rabbit . PubMed: 25617133
- Lisk C et al. Nrf2 activation: a potential strategy for the prevention of acute mountain sickness. Free Radic Biol Med 63:264-73 (2013). IHC-P ; Rat . PubMed: 23722164
- Chabot S et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med 208:973-86 (2011). IHC . PubMed: 21482699
- Ramaswamy S et al. The role of organ level conditioning on the promotion of engineered heart valve tissue development in-vitro using mesenchymal stem cells. Biomaterials 31:1114-25 (2010). IHC . PubMed: 19944458
- Chen X et al. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflammation 5:12 (2008). IHC-Fr ; Rabbit . PubMed: 18387175
- Naiem M et al. The value of immunohistological screening in the production of monoclonal antibodies. J Immunol Methods 50:145-60 (1982). PubMed: 6806388